Search

Author/Creator Drappa, Jorn

1. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Issue 1 (23rd February 2013)

Authors:
Higgs, Brandon W; Zhu, Wei; Morehouse, Chris; White, Wendy I; Brohawn, Philip; Guo, Xiang; Rebelatto, Marlon; Le, Chenxiong; Amato, Anthony; Fiorentino, David; Greenberg, Steven A; Drappa, Jorn; Richman, Laura; Greth, Warren; Jallal, Bahija; Yao, Yihong
Journal:
Annals of the rheumatic diseases
Issue:
Volume 73:Issue 1(2014)
Page Start:
256
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. Issue 1 (26th November 2018)

Authors:
Merrill, Joan T; Furie, Richard; Werth, Victoria P; Khamashta, Munther; Drappa, Jorn; Wang, Liangwei; Illei, Gabor; Tummala, Raj
Journal:
Lupus science & medicine
Issue:
Volume 5:Issue 1(2018)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus. Issue 2 (28th January 2017)

Authors:
Furie, Richard; Khamashta, Munther; Merrill, Joan T.; Werth, Victoria P.; Kalunian, Kenneth; Brohawn, Philip; Illei, Gabor G.; Drappa, Jorn; Wang, Liangwei; Yoo, Stephen
Journal:
Arthritis & rheumatology
Issue:
Volume 69:Issue 2(2017)
Page Start:
376
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus. Issue 2 (February 2017)

Authors:
Furie, Richard; Khamashta, Munther; Merrill, Joan T.; Werth, Victoria P.; Kalunian, Kenneth; Brohawn, Philip; Illei, Gabor G.; Drappa, Jorn; Wang, Liangwei; Yoo, Stephen
Journal:
Arthritis & rheumatology
Issue:
Volume 69:Issue 2(2017)
Page Start:
376
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. Issue 3 (May 2021)

Authors:
Marignier, Romain; Bennett, Jeffrey L.; Kim, Ho Jin; Weinshenker, Brian G.; Pittock, Sean J.; Wingerchuk, Dean; Fujihara, Kazuko; Paul, Friedemann; Cutter, Gary R.; Green, Ari J.; Aktas, Orhan; Hartung, Hans-Peter; Lublin, Fred D.; Williams, Ian M.; Drappa, Jorn; She, Dewei; Cimbora, Daniel; Rees...
Journal:
Neurology
Issue:
Volume 8:Issue 3(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double‐Blind, Phase III Study. Issue 9 (26th August 2013)

Authors:
Mysler, Eduardo F.; Spindler, Alberto J.; Guzman, Renato; Bijl, Marc; Jayne, David; Furie, Richard A.; Houssiau, Frédéric A.; Drappa, Jorn; Close, David; Maciuca, Romeo; Rao, Kajal; Shahdad, Saba; Brunetta, Paul
Journal:
Arthritis and rheumatism
Issue:
Volume 65:Issue 9(2013:Sep.)
Page Start:
2368
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double‐Blind, Phase III Study1. Issue 9 (26th August 2013)

Authors:
Mysler, Eduardo F.; Spindler, Alberto J.; Guzman, Renato; Bijl, Marc; Jayne, David; Furie, Richard A.; Houssiau, Frédéric A.; Drappa, Jorn; Close, David; Maciuca, Romeo; Rao, Kajal; Shahdad, Saba; Brunetta, Paul
Journal:
Arthritis and rheumatism
Issue:
Volume 65:Issue 9(2013:Sep.)
Page Start:
2368
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Issue 10206 (12th October 2019)

Authors:
Cree, Bruce A C; Bennett, Jeffrey L; Kim, Ho Jin; Weinshenker, Brian G; Pittock, Sean J; Wingerchuk, Dean M; Fujihara, Kazuo; Paul, Friedemann; Cutter, Gary R; Marignier, Romain; Green, Ari J; Aktas, Orhan; Hartung, Hans-Peter; Lublin, Fred D; Drappa, Jorn; Barron, Gerard; Madani, Soraya; Ratchfo...
Journal:
Lancet
Issue:
Volume 394:Issue 10206(2019)
Page Start:
1352
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial. (May 2022)

Authors:
Rensel, Mary; Zabeti, Aram; Mealy, Maureen A; Cimbora, Daniel; She, Dewei; Drappa, Jorn; Katz, Eliezer
Journal:
Multiple sclerosis
Issue:
Volume 28:Number 6(2022)
Page Start:
925
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗